Table 1.
The baseline characteristics of Hodgkin-lymphoma (HL) patients.
| All patients (n:30) | |
|---|---|
| Median age at T1 = diagnosis time (years) | 33 (20-69) |
| Median age at T2 (years) | 33 (21-63) |
| Median age at T3 (years) | 40 (29-70) |
| Time elapsed T1-T2 (months) | 7 (5-13) |
| Time elapsed T1-T3 (years) | 8,6 (0-11) |
| Male | 14 (46%) |
| Female | 16 (54%) |
| Place of permanent residence | |
| Village | 4 (13%) |
| City | 26 (87%) |
| Education level | |
| High school or below | 22 (73%) |
| College or above | 8 (27%) |
| Active employment status | 22 (73%) |
| Inactive empolyment status | 8 (27%) |
| HL stage | |
| I | 0 |
| II | 6 (20%) |
| III | 5 (16%) |
| IV | 19 (64%) |
| Bulk disease | 11 (36%) |
| Without bulk | 19 (64%) |
| B symptom | 19 (64%) |
| No B symptom | 11 (36%) |
| ECOG performance status | |
| 0 | 29 (96%) |
| 1 | 1 (4%) |
| Comorbidity | 6 (20%) |
| No comorbidity | 24 (80%) |
| Treatment | |
| ABVD | 22 (73%) |
| A+AVD | 8 (27%) |
| Irradiation | 12 (40%) |
| No irradiation | 18 (60%) |
| Primary treatment response | |
| Complete remission | 26 (87%) |
| Partial remission | 2 (6,5%) |
| Stable disease | 2 (6,5%) |
| Treatment-related side effect | |
| Yes | 9 (30%) |
| No | 21 (70%) |
| Relapse / No response | 4 (13%) |
| No relapse | 26 (86%) |
B symptoms: fever, night sweats and unintentional weight loss; ECOG PS, Eastern Cooperative Oncology Group performance status; ABVD, adriamycin, bleomycin, vinblastin and dacarbazin; A+AVD, brentuximab vedotin, doxorubicin, vinblastin, dacarbazin.